Do androgens raise hematocrit before hemoglobin becomes abnormal?

Androgens are potent stimulators of red blood cell production, and clinical evidence confirms that their administration can cause a disproportionate rise in hematocrit relative to hemoglobin. This phenomenon is particularly relevant in the context of testosterone replacement therapy (TRT) and androgen-driven erythrocytosis.

Clinical evidence and metrics

Research indicates a distinct quantitative dissociation between hematocrit (Hct) and hemoglobin (Hb) during androgen treatment. While both markers typically increase, the Hct/Hb ratio—which is normally approximately 3:1—rises significantly (p < 0.0001).

• In one clinical dataset, androgen therapy raised median Hct from 44% to 49%, while Hb rose more modestly from 14.5 to 14.9 g/dL.
• This disproportionate increase means a patient can reach threshold levels for polycythemia (e.g., Hct >50–54%) while their hemoglobin concentration remains within or near the normal range.
• Studies consistently show Hct increases of approximately 4% and Hb increases of approximately 8% relative to baseline, but the timing and magnitude of these changes favor an earlier Hct abnormality.

Mechanistic explanations

The stimulation of erythropoiesis and the subsequent "Hct-Hb dissociation" are driven by several integrated biological pathways:

• EPO Stimulation: Androgens activate androgen receptors (AR) in the kidneys and other non-hematopoietic cells, leading to increased production of erythropoietin (EPO), which stimulates bone marrow red cell production.
• Hepcidin Suppression: Testosterone suppresses hepcidin (the master regulator of iron), both directly and via increased erythroferrone. This enhances iron mobilization through ferroportin, facilitating rapid red cell manufacturing.
• Plasma Volume Contraction: The primary driver for Hct rising before Hb is androgen-induced contraction of plasma volume. Because Hct measures the volume percentage of red cells, a decrease in the liquid (plasma) component of blood concentrates the red cells, inflating the Hct value more significantly than the total mass of hemoglobin.

Bottom line

Androgens stimulate erythropoiesis and simultaneously reduce plasma volume, which often causes hematocrit to reach clinically abnormal levels before hemoglobin does. Monitoring both parameters is essential, as hematocrit is the more sensitive indicator of androgen-induced erythrocytosis.